137 related articles for article (PubMed ID: 33283706)
21. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG).
Asai D; Imamura T; Yamashita Y; Suenobu S; Moriya-Saito A; Hasegawa D; Deguchi T; Hashii Y; Endo M; Hatakeyama N; Kawasaki H; Hori H; Horibe K; Yumura-Yagi K; Hara J; Watanabe A; Kikuta A; Oda M; Sato A;
Cancer Med; 2014 Jun; 3(3):623-31. PubMed ID: 24578304
[TBL] [Abstract][Full Text] [Related]
22. [A clinical and laboratory study of TCF3-PBX1 positive adult acute lymphoblastic leukemia.].
Zheng JF; Qiu HY; Pan JL; Cen JN; Wu YF; Zhang J; Wu DP; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2010 Jan; 31(1):16-20. PubMed ID: 20302770
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds].
Wei T; Chen XJ; Zhang LY; Zhang AL; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1279-1285. PubMed ID: 33327998
[TBL] [Abstract][Full Text] [Related]
24. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
Paulsson K; Jonson T; Ora I; Olofsson T; Panagopoulos I; Johansson B
Br J Haematol; 2007 Jul; 138(2):196-201. PubMed ID: 17593026
[TBL] [Abstract][Full Text] [Related]
26. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
[TBL] [Abstract][Full Text] [Related]
27. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia.
Samra MA; Mahmoud HK; Abdelhamid TM; El Sharkawy NM; Elnahass YH; Elgammal M; Abdelfattah RM; Eid S; Ghaleb FM; Kamel AM
J Egypt Natl Canc Inst; 2013 Sep; 25(3):135-42. PubMed ID: 23932750
[TBL] [Abstract][Full Text] [Related]
29. Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion.
Rowsey RA; Smoley SA; Williamson CM; Vasmatzis G; Smadbeck JB; Ning Y; Greipp PT; Hoppman NL; Baughn LB; Ketterling RP; Peterson JF
Blood Cancer J; 2019 Oct; 9(10):81. PubMed ID: 31575852
[TBL] [Abstract][Full Text] [Related]
30. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
31. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Eldfors S; Kuusanmäki H; Kontro M; Majumder MM; Parsons A; Edgren H; Pemovska T; Kallioniemi O; Wennerberg K; Gökbuget N; Burmeister T; Porkka K; Heckman CA
Leukemia; 2017 Jan; 31(1):51-57. PubMed ID: 27461063
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Felice MS; Gallego MS; Alonso CN; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Zubizarreta PA; Rossi JG
Leuk Lymphoma; 2011 Jul; 52(7):1215-21. PubMed ID: 21534874
[TBL] [Abstract][Full Text] [Related]
33. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
34. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
Modvig S; Hallböök H; Madsen HO; Siitonen S; Rosthøj S; Tierens A; Juvonen V; Osnes LTN; Vålerhaugen H; Hultdin M; Matuzeviciene R; Stoskus M; Marincevic M; Lilleorg A; Ehinger M; Norén-Nystrøm U; Toft N; Taskinen M; Jónsson OG; Pruunsild K; Vaitkeviciene G; Vettenranta K; Lund B; Abrahamsson J; Porwit A; Schmiegelow K; Marquart HV
Leukemia; 2021 Jul; 35(7):1894-1906. PubMed ID: 33318611
[TBL] [Abstract][Full Text] [Related]
35. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment.
Burmeister T; Gröger D; Gökbuget N; Spriewald B; Starck M; Elmaagacli A; Hoelzer D; Keller U; Schwartz S
Sci Rep; 2023 Sep; 13(1):15167. PubMed ID: 37704696
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
38. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
39. [Correlation Analysis between Cerebrospinal Fluid Status and Prognosis in Childhood with Acute Lymphoblastic Leukemia by Flow Cytometry].
Ding LL; Xiong H; Yang L; Chen Y; DU Y; Lu WJ; Qi SS; Chen Z; Sun M; Luo LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):654-658. PubMed ID: 37356922
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
